DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qf5qtv/u_s_colony) has announced the addition of the "U.S. Colony Stimulating Factors Market" report to their offering.
In August 2012, the FDA approved Teva's tbo-filgrastim. The approval was based on a full Biologic License Application (BLA) rather than under the FDA's new biosimilar approval pathway.
Due to a court ruling related to Amgen's filgrastim patents, Teva will be able to start selling its product in the US on November 10th, 2013. This is the first serious challenge to Amgen's US filgrastim franchise, currently worth $4.4 billion.
Other companies with filgrastim molecules ready to enter the US market include Apotex, Celgene, Hospira, Merck, Reliance Life Sciences, Novartis (Sandoz) and Roche.
The US Colony Stimulating Factors Report examines both the current and future landscapes of the US G-CSFs market with in-depth analysis of Amgen's market position and three scenarios of how the market might evolve in 2014, and beyond.
Targeted at senior executives in the biopharmaceutical industry, the report offers an insightful review of the opportunities available for follow-on biologics in the space and volunteers a forecast to 2020.
Key Topics Covered:
1. US Pharmaceutical Market Trends
2. US Biopharmaceuticals Market Trends
3. US Colony Stimulating Factors Market
4. Amgen's Filgrastim Franchise
5. Teva Filgrastim Franchise
6. Potential New Entrants
7. US Colony Stimulating Factors Market Forecast
Tables & Figures
- Reliance Life Sciences
For more information visit http://www.researchandmarkets.com/research/qf5qtv/u_s_colony
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.